Atriva Therapeutics GmbH Employee Directory

Biotechnology ResearchGermany2-10 Employees

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany.

Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de
For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter (@AtrivaTx).

Sign up for free to view info

Company overview Email format